Last reviewed · How we verify
Rifapentine (RPT)
Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria.
Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria. Used for Tuberculosis (TB), including drug-susceptible and latent TB infection, Pulmonary tuberculosis as part of combination therapy.
At a glance
| Generic name | Rifapentine (RPT) |
|---|---|
| Also known as | Priftin, Rifamycin |
| Sponsor | Walter K. Kraft |
| Drug class | Rifamycin antibiotic |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rifapentine is a rifamycin antibiotic that binds to the bacterial RNA polymerase enzyme and blocks RNA synthesis in mycobacteria. It has a longer half-life than rifampicin, allowing for less frequent dosing. It is bactericidal against Mycobacterium tuberculosis and is used as part of combination therapy for tuberculosis.
Approved indications
- Tuberculosis (TB), including drug-susceptible and latent TB infection
- Pulmonary tuberculosis as part of combination therapy
Common side effects
- Hepatotoxicity
- Hyperuricemia
- Gastrointestinal disturbances
- Rash
- Drug interactions (enzyme induction)
Key clinical trials
- A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV (PHASE1, PHASE2)
- One-month Latent Tuberculosis Treatment for Renal Transplant Candidates (PHASE4)
- Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV (PHASE1, PHASE2)
- Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis (PHASE2)
- 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam (PHASE3)
- Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals (PHASE3)
- Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT (PHASE3)
- Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifapentine (RPT) CI brief — competitive landscape report
- Rifapentine (RPT) updates RSS · CI watch RSS
- Walter K. Kraft portfolio CI